Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ko Kim

Nurse Practitioner Chapel Hill, NC Nurse Practitioner

NPI 1811668841 CMS profile 10383696

374 Mallard Landing Dr, Chapel Hill, NC 27516

Open in the dashboard

General payments

$8,304

331 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ko Kim of Chapel Hill, NC is reported in the CMS Open Payments database as having received $8,304 across 331 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,223 136
2024 General $3,005 94
2023 General $1,819 86
2022 General $244 14
2021 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ko Kim
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Ko Kim were reported at $3,223. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Ko Kim Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $14 $135 $40–$426 $132
2022 $244 $152 $48–$470 $149
2023 $1,819 $166 $54–$529 $160
2024 $3,005 $173 $55–$556 $164
2025 $3,223 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Scilex Pharmaceuticals Inc. $1,120 65 payments
  2. LivaNova USA, Inc. $847 4 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $694 35 payments
  4. Forte Bio-Pharma LLC $547 27 payments
  5. SI-BONE, Inc. $537 2 payments
  6. Axsome Therapeutics, Inc. $496 15 payments
  7. Nevro Corp. $462 9 payments
  8. Valinor Pharma, LLC $373 19 payments
  9. Globus Medical, Inc. $368 8 payments
  10. AbbVie, Inc. $335 20 payments
  11. Other $2,526 127 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,250 327 payments
  2. Travel and Lodging $1,011 3 payments
  3. Education $43 1 payment
Products named General payments · program years 2021–2025
  1. ZTLido $1,120 65 payments
  2. VNS Therapy $847 4 payments
  3. IFUSE IMPLANT SYSTEM $522 1 payment
  4. PROLATE Pain $497 26 payments
  5. PROLATE Pain $497 26 payments
  6. PROLATE Pain $497 26 payments
  7. NALOCET $497 26 payments
  8. Sunosi $496 15 payments
  9. Senza $462 9 payments
  10. RELISTOR $413 23 payments
  11. Other $4,710 235 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

5,011

Median for Nurse Practitioner: 389

Drug cost

$820,910

Median for Nurse Practitioner: $21,885

Branded share of claims

52.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 387 $167,012
Relistor Methylnaltrexone Bromide Brand 39 $106,781
Ztlido Lidocaine Brand 85 $83,015
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,033 $41,793
Nurtec Odt Rimegepant Sulfate Brand 35 $39,461
Buprenorphine Generic 158 $36,552
Linzess Linaclotide Brand 56 $36,129
Oxycontin Oxycodone Hcl Brand 75 $35,918
Belbuca Buprenorphine Hcl Brand 60 $32,120
Nucynta Er Tapentadol Hcl Brand 50 $30,107

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$83,426

Of which drugs: $80

Medicare patients

115

Average age 67

Services billed

1,683

60 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 52%
Depression 40%
Ischemic heart disease 37%
COPD 37%
Chronic kidney disease 28%
Heart failure 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 84 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $392
$392 85 —
MOVANTIK
  • Valinor Pharma, LLC $307
$307 34 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $192
$192 39 —
Leqembi
  • Eisai Inc. $165
$165 — —
Sunosi
  • Axsome Therapeutics, Inc. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

331 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record